Amarin Corporation/$AMRN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Amarin Corporation

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.

Ticker

$AMRN
Sector
Primary listing

Employees

-

Headquarters

Dublin, Ireland

AMRN Metrics

BasicAdvanced
$310M
-
-$5.02
0.78
-

Bulls say / Bears say

The exclusive long-term licensing and supply agreement with Recordati secures a $25 million upfront payment and potential $150 million in milestone payments, providing significant non-dilutive funding and accelerating VAZKEPA’s commercialization in 59 European markets (Nasdaq).
Amarin ended Q2 2025 with $298.7 million in cash and no debt, ensuring ample liquidity to support operations, fund growth initiatives, and weather ongoing market challenges (Nasdaq).
European revenue in Q1 2025 surged to $5.4 million from $1.9 million a year earlier, highlighting robust ex-U.S. demand and early momentum for VAZKEPA in core markets such as Spain and the UK (Nasdaq).
U.S. net product revenue declined 17% year-over-year in Q2 2025 to $36.5 million amid intensified generic competition, undermining the company’s core U.S. cash flow generator (Nasdaq).
Amarin posted a net loss of $14.1 million, or $0.03 per ADS, in Q2 2025 versus net income of $1.5 million in Q2 2024, reflecting ongoing profitability challenges (Amarin).
The recognition of $22.8 million in restructuring charges in Q2 2025 to streamline global operations introduces execution risk and places short-term pressure on operating results (Amarin).
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AMRN

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs